Clinical Trials

ZW25 (Anti-HER2 x HER2 Bispecific Antibody)

ZW25 is a bispecific HER2-targeting antibody therapeutic for the treatment of patients with HER2-expressing cancers, currently being evaluated in a Phase 2 clinical trial.

Study Title: Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers

Start Date: September 2016

For more details regarding this trial, including eligibility criteria, please visit clinicaltrials.gov.

Study Title: Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA)

Start Date: April 2019

For more details regarding this trial, including eligibility criteria, please visit clinicaltrials.gov.

ZW49 (Anti-HER2 x HER2 ADC)

ZW49 is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload, currently being evaluated in a Phase 1 clinical trial.

Study Title: A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Start Date: January 2019

For more details regarding this trial, including eligibility criteria, please visit clinicaltrials.gov.